LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $9.00 at Barclays

LifeStance Health Group (NASDAQ:LFST) had its price target raised by Barclays from $8.00 to $9.00 in a research note released on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts have also recently commented on LFST. Weiss Ratings upgraded LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 27th. BTIG Research raised their price target on LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, February 2nd. KeyCorp upped their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. UBS Group increased their target price on shares of LifeStance Health Group from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, Wall Street Zen upgraded shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.83.

LifeStance Health Group Stock Performance

NASDAQ:LFST traded down $0.02 during mid-day trading on Friday, hitting $6.93. The stock had a trading volume of 2,955,097 shares, compared to its average volume of 2,880,011. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17. The company has a 50 day simple moving average of $7.13 and a 200-day simple moving average of $6.27. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of 346.67 and a beta of 1.11. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.09.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, February 25th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.02). The firm had revenue of $382.20 million during the quarter, compared to the consensus estimate of $378.51 million. LifeStance Health Group had a return on equity of 0.65% and a net margin of 0.68%.LifeStance Health Group’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.01) EPS. On average, research analysts expect that LifeStance Health Group will post -0.18 earnings per share for the current fiscal year.

LifeStance Health Group declared that its board has initiated a stock buyback program on Wednesday, February 25th that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 3.6% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling at LifeStance Health Group

In other news, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total transaction of $345,000.00. Following the completion of the sale, the insider directly owned 315,610 shares of the company’s stock, valued at $2,177,709. This represents a 13.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Darren M. Black sold 4,314,939 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $7.01, for a total value of $30,247,722.39. Following the completion of the transaction, the director owned 29,209,776 shares of the company’s stock, valued at $204,760,529.76. This trade represents a 12.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 4,585,025 shares of company stock valued at $32,138,986. Corporate insiders own 3.20% of the company’s stock.

Institutional Trading of LifeStance Health Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Larson Financial Group LLC increased its position in shares of LifeStance Health Group by 19,952.6% in the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after acquiring an additional 3,791 shares in the last quarter. Bayesian Capital Management LP purchased a new position in shares of LifeStance Health Group during the second quarter valued at $52,000. Krane Funds Advisors LLC acquired a new position in LifeStance Health Group during the fourth quarter valued at $71,000. Vanguard Personalized Indexing Management LLC purchased a new stake in LifeStance Health Group in the 3rd quarter worth about $72,000. Finally, Cibc World Markets Corp acquired a new stake in LifeStance Health Group during the 4th quarter worth about $77,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.